Stefan Gluck

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. doi request reprint Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases
    Stefan Gluck
    Division of Hematology Oncology, Braman Family Breast Cancer Institute, UM Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
    Am J Ther 16:585-90. 2009
  2. doi request reprint Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis
    S Gluck
    Department of Medicine, Division of Hematology Oncology, University of Miami, Leonard M Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Miami, FL 33136, USA Electronic address
    Breast 22:1087-93. 2013
  3. doi request reprint Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy
    Stefan Gluck
    Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Avenue, Suite 3510, Miami, FL 33136, USA
    Breast Cancer Res Treat 139:759-67. 2013
  4. doi request reprint Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer
    Stefan Gluck
    Department of Medicine, Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Leonard M Miller School of Medicine, 1475 NW 12th Ave, Miami, FL 33136, USA
    Breast 22:142-9. 2013
  5. doi request reprint TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
    Stefan Gluck
    Division of Hematology Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Leonard M Miller School of Medicine, 1475 NW 12th Ave, Suite 3510, Miami, FL 33136, USA
    Breast Cancer Res Treat 132:781-91. 2012
  6. ncbi request reprint Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?
    Stefan Gluck
    University of Miami, Leonard M Miller School of Medicine, Sylvester Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, 1475 NW 12th Ave, Suite 3510, Miami, FL 33136, USA
    Expert Opin Ther Targets 16:S17-22. 2012
  7. ncbi request reprint The prevention and management of distant metastases in women with breast cancer
    Stefan Gluck
    Division of Hematology Oncology, Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA
    Cancer Invest 25:6-13. 2007
  8. ncbi request reprint Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin
    Stefan Gluck
    Miller School of Medicine, University of Miami, Florida, USA
    Oncologist 10:780-91. 2005
  9. ncbi request reprint Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition
    S Gltick
    Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center, University of Miami School of Medicine, FL, USA
    Biomed Pharmacother 59:S321-2. 2005
  10. doi request reprint Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer
    Stefan Gluck
    Division of Hematology Oncology, Leonard M Miller School of Medicine, University of Miami, FL, USA
    Am J Health Syst Pharm 68:1699-706. 2011

Collaborators

Detail Information

Publications34

  1. doi request reprint Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases
    Stefan Gluck
    Division of Hematology Oncology, Braman Family Breast Cancer Institute, UM Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
    Am J Ther 16:585-90. 2009
    ..Lapatinib plus capecitabine seems to have clinical activity in HER2-positive brain metastases...
  2. doi request reprint Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis
    S Gluck
    Department of Medicine, Division of Hematology Oncology, University of Miami, Leonard M Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Miami, FL 33136, USA Electronic address
    Breast 22:1087-93. 2013
    ..2 versus 3.5 months; HR 0.73, 95% CI: 0.53-0.98; P = 0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation. ..
  3. doi request reprint Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy
    Stefan Gluck
    Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Avenue, Suite 3510, Miami, FL 33136, USA
    Breast Cancer Res Treat 139:759-67. 2013
    ..BluePrint with MammaPrint molecular subtyping helps to improve prognostic estimation and the choice of therapy versus IHC/FISH. ..
  4. doi request reprint Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer
    Stefan Gluck
    Department of Medicine, Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Leonard M Miller School of Medicine, 1475 NW 12th Ave, Miami, FL 33136, USA
    Breast 22:142-9. 2013
    ..To provide evidence-based treatment guidance, future clinical trials should include more patients over the age of 65 years...
  5. doi request reprint TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
    Stefan Gluck
    Division of Hematology Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Leonard M Miller School of Medicine, 1475 NW 12th Ave, Suite 3510, Miami, FL 33136, USA
    Breast Cancer Res Treat 132:781-91. 2012
    ..TP53 mutational analysis and genomic subtyping were predictive...
  6. ncbi request reprint Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?
    Stefan Gluck
    University of Miami, Leonard M Miller School of Medicine, Sylvester Comprehensive Cancer Center, Division of Hematology Oncology, Department of Medicine, 1475 NW 12th Ave, Suite 3510, Miami, FL 33136, USA
    Expert Opin Ther Targets 16:S17-22. 2012
    ..However, additional important clinical information is added to traditional histology and IHC determination of ER, PR and HER2 in terms of prognostic and predictive power...
  7. ncbi request reprint The prevention and management of distant metastases in women with breast cancer
    Stefan Gluck
    Division of Hematology Oncology, Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA
    Cancer Invest 25:6-13. 2007
    ..New third-generation aromatase inhibitors (anastrozole, exemestane, and letrozole) that have been shown to be well tolerated have the potential to contribute to benefits beyond those seen with tamoxifen...
  8. ncbi request reprint Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin
    Stefan Gluck
    Miller School of Medicine, University of Miami, Florida, USA
    Oncologist 10:780-91. 2005
    ....
  9. ncbi request reprint Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition
    S Gltick
    Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center, University of Miami School of Medicine, FL, USA
    Biomed Pharmacother 59:S321-2. 2005
    ....
  10. doi request reprint Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer
    Stefan Gluck
    Division of Hematology Oncology, Leonard M Miller School of Medicine, University of Miami, FL, USA
    Am J Health Syst Pharm 68:1699-706. 2011
    ..The clinical and economic benefits of aromatase inhibitor (AI) therapy in early-stage breast cancer are reviewed...
  11. doi request reprint Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient
    Stefan Gluck
    University of Miami s Sylvester Comprehensive Cancer Center, Miami, Florida, USA
    Clin Cancer Res 17:5559-61. 2011
    ....
  12. ncbi request reprint New advances in the management of metastatic breast cancer
    Stefan Gluck
    Department of Medicine, University of Miami, Miller School of Medicine, UM Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Suite 3510, Miami, FL 33136, USA
    J Natl Compr Canc Netw 3:S12-6. 2005
  13. doi request reprint Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer
    Stefan Gluck
    Division of Hematology Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, 1475 NW 12th Avenue, Miami, FL 33136, USA
    Am J Clin Oncol 33:314-9. 2010
    ....
  14. pmc XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer
    Stefan Gluck
    Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Int J Med Sci 5:341-6. 2008
    ..In XeNA, the sum of pCR and npCR will facilitate correlative studies designed to identify patients most likely to benefit from XT and HXT and may expedite the clinical evaluation of these novel preoperative regimens...
  15. doi request reprint Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Christopher Lobo
    Florida Cancer Specialists and Research Institute, Gainesville, FL, USA
    Breast Cancer Res Treat 123:427-35. 2010
    ..First-line therapy with nab-P, B, and G demonstrated a median PFS of 10.4 months and a 75.9% ORR with acceptable toxicity; this novel combination warrants investigation in a randomized study...
  16. doi request reprint Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer
    Kristin M Phillips
    Department of Psychology, University of Miami, Coral Gables, Florida 33124, USA
    Psychosom Med 70:1044-9. 2008
    ....
  17. doi request reprint A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer
    Orlando Silva
    Division of Hematology and Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
    Clin Breast Cancer 8:162-7. 2008
    ..A schedule with split, low-dose docetaxel in combination with low-dose capecitabine could improve the therapeutic index of this regimen without compromising its clinical activity...
  18. ncbi request reprint Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute
    Christopher Lobo
    Division of Hematology Oncology, Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, 1475 NW 12th Avenue, Suite 3510, Miami, FL 33136, USA
    Biomed Pharmacother 61:531-3. 2007
    ..Ongoing investigational efforts are evaluating various doublets with these agents, but, to the best of our knowledge, not all 3 of them in the same regimen. All drugs are currently FDA-approved in the treatment of cancer...
  19. doi request reprint Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature
    Alberto J Montero
    Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136 1002, USA
    Am J Ther 18:e12-8. 2011
    ....
  20. doi request reprint A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
    Alberto J Montero
    Division of Hematology Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
    Breast Cancer Res Treat 132:747-51. 2012
    ..Bevacizumab plus paclitaxel is not cost-effective in treating MBC. Value-based pricing and the development of biomarkers to improve patient selection are needed to better define the role of the drug in this population...
  21. ncbi request reprint Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Aurelio B Castrellon
    Division of Hematology Oncology, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
    Clin Adv Hematol Oncol 6:666-72. 2008
    ..Further trials are needed to determine the optimal length of adjuvant therapy with trastuzumab, as well as long-term side effects with special attention to cardiotoxicity...
  22. doi request reprint Macrophages as independent prognostic factors in small T1 breast cancers
    Roberto Carrio
    Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Oncol Rep 29:141-8. 2013
    ....
  23. doi request reprint Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review
    Alberto J Montero
    Department of Medicine, Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Leonard M Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA
    Expert Rev Clin Pharmacol 4:329-34. 2011
    ..While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article...
  24. pmc Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
    Alberto J Montero
    UM Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
    Curr Oncol Rep 14:1-11. 2012
    ..This review looks at all available phase 3 data with bevacizumab in the MBC setting to determine whether the data support this decision by the FDA, and discusses the future of bevacizumab in breast cancer...
  25. doi request reprint Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer
    Hyo Sook Han
    Department of Women s Oncology, Breast Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Eur J Cancer 47:2537-45. 2011
    ..We hypothesised that racial/ethnic differences result in differential tolerance to chemotherapy potentially, leading to compromised dose intensity/density of chemotherapy in patients with early-stage breast cancer...
  26. doi request reprint Surviving metastatic breast cancer for 18 years: a case report and review of the literature
    Soley Bayraktar
    Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida 33136, USA
    Breast J 17:521-4. 2011
    ..To the authors' knowledge, this is the first reported case in the literature with the longest overall survival in a patient with MBC. We provide a detailed clinical analysis in conjunction with a brief literature review...
  27. doi request reprint Chemoprevention of breast cancer
    Aurelio B Castrellon
    University of Miami Miller s School Of Medicine, Division of Hematology Medical Oncology, Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue Miami, FL 33136, USA
    Expert Rev Anticancer Ther 8:443-52. 2008
    ..Herein, we review the most important chemopreventive agents in breast cancer and clinical trials that have evaluated their efficacy...
  28. pmc Treating breast cancer in the 21st century: emerging biological therapies
    Gabriel Tinoco
    1 Department of Medicine, Division of Hospital Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    J Cancer 4:117-32. 2013
    ....
  29. doi request reprint Systemic therapy options in BRCA mutation-associated breast cancer
    Soley Bayraktar
    Department of Medicine, Division of Hematology Medical Oncology, University of Miami and Sylvester Comprehensive Cancer Center, Miami, FL, USA
    Breast Cancer Res Treat 135:355-66. 2012
    ..The optimal chemotherapy regimen for this subset of patients still remains to be determined...
  30. ncbi request reprint Improving outcomes in early-stage breast cancer
    Stefan Gluck
    Division of Hematology Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA
    Oncology (Williston Park) 24:1-15. 2010
    ..The focus is on appropriate, evidence-based treatment of this patient population...
  31. ncbi request reprint How stress management improves quality of life after treatment for breast cancer
    Michael H Antoni
    Department of Psychology, University of Miami, Miami, FL 33146, USA
    J Consult Clin Psychol 74:1143-52. 2006
    ..Thus, this intervention had beneficial effects on diverse aspects of quality of life after treatment for breast cancer, which appear linked to a specific stress management skill taught in the intervention...
  32. doi request reprint Participation in cancer clinical trials: why are patients not participating?
    Margaret M Byrne
    Department of Public Health Sciences MMB, University of Miami Miller School of Medicine, Miami, Florida
    Med Decis Making 34:116-26. 2014
    ..The objective of this study was to determine what factors are associated with patients' participation or willingness to participate and whether these factors vary by race/ethnicity...
  33. pmc Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review
    Roberto Ochoa
    Sylvester Comprehensive Cancer Center, University of Miami, Leonard M, Miller School of Medicine, 1475 N, W, 12th Avenue Suite 3410, Miami, FL 33136, USA
    J Med Case Rep 6:413. 2012
    ..abstract:..
  34. ncbi request reprint Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer
    Samer I Schuman
    Division of Gynecologic Oncology, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, SCCC 3500, Miami, FL 33136, USA
    J Support Oncol 7:225-8. 2009
    ..Administration of pegfilgrastim on the same day as myelosuppressive chemotherapy in patients with ovarian or primary peritoneal cancer may be determined to be a convenient, safe, and effective approach...